Phenominer Database Results (17 results)

 
 
Table "column sort" updates the order of the bars in the chart.
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Site Method Duration Post Insult Type Post Insult Time Value Post Insult Time Unit Method Notes Record ID Study ID
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug/200 ul) Jagodic M, et al., J Immunol 2005 Jan 15;174(2):918-24. central nervous system integrity trait both 63 days-150 days 20 60.0 % in vivo visual assessment 0.0 intradermal injection 0 from p.i. day 7 68124 838
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 8 100.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67850 829
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 16 87.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67853 829
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 10 80.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68706 839
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait male 91 days-112 days 22 82.0 % in vivo visual assessment 0.0 0 visual observation 69487 837
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug/200 ul) Jagodic M, et al., J Immunol 2005 Jan 15;174(2):918-24. central nervous system integrity trait both 63 days-150 days 23 100.0 % in vivo visual assessment 0.0 intradermal injection 0 from p.i. day 7 68128 838
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 37 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 28 64.0 % in vivo visual assessment 0.0 subcutaneous injection 37 days from 8 to 37 days 69378 892
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 10 100.0 % in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days 69409 892
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (0.09 ug/g) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 91 days-112 days 0 89.0 % 33.0 in vivo visual assessment 0.0 0 visual observation 69497 837
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 16 50.0 % in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days 69384 892
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (15-22 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 91 days-112 days 12 92.0 % in vivo visual assessment 0.0 0 68122 837
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 10 80.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67849 829
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 11 100.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68132 839
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 18 94.0 % in vivo visual assessment 0.0 subcutaneous injection 38 days from 8 to 38 days 69390 892
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 16 87.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67852 829
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 12 50.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68710 839
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 10 80.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68714 839